ConductScience.org, home

Comparison · NCT00524472-sae

Hyperinsulinemic-normoglycemic Clamp vs Insulin at the Standard of Care Levels: serious adverse events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Hyperinsulinemic-normoglycemic Clamp vs Insulin at the Standard of Care Levels: serious adverse events. Trial comparisons, record NCT00524472-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00524472-sae

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.02540.01610.0398wilson
Risk in group 20.0370.02550.0533wilson
Risk difference, group 1 minus group 2-0.0116-0.03030.00678newcombe hybrid score
Risk ratio, group 1 over group 20.6860.3811.24log
Odds ratio, group 1 over group 20.6780.371.24log
Number needed to treat, for one fewer participant with a serious adverse event on Hyperinsulinemic-normoglycemic Clamp than on Insulin at the Standard of Care Levels86.2from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: standard of care.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Hyperinsulinemic-normoglycemic Clamp
Patients will be randomized to receive the hyperinsulinemic-normoglycemic clamp titrating the blood glucose to 80-110 mg/dL.~Hyperinsulinemic-normoglycemic clamp: Patients will be randomized to receive the hyperinsulinemic-normoglycemic clamp titrating the blood glucose to 80-110 mg/dL.
18709EG000
Group 2Insulin at the Standard of Care Levels
Group B will be administered insulin at the standard of care levels established by the participating institution.~insulin at the standard of care levels: Subjects will be administered insulin at the standard of care levels established by the participating institution.
27730EG001

Harm

What it counts
Total, serious adverse events
Time frame
One Year Post-opeperative follow-up for All-Cause Mortality; 1 month Post-opeperative follow-up for Serious Adverse Events and Other (Not Including Serious) Adverse Events

Source ClinicalTrials.gov

Trial

Title
Outcomes Study of Hyperinsulinemic Glucose Control in Cardiac Surgery
NCT number
NCT00524472
Phases
NA
Conditions
Cardiac Surgery
Interventions
Hyperinsulinemic-normoglycemic clamp, insulin at the standard of care levels
Lead sponsor
The Cleveland Clinic
Results first posted
2018-10-26

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00524472-sae